Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.72 USD | +0.64% | +5.25% | -8.73% |
Financials (USD)
Sales 2024 * | 695M | Sales 2025 * | 760M | Capitalization | 1.42B |
---|---|---|---|---|---|
Net income 2024 * | 58M | Net income 2025 * | 82M | EV / Sales 2024 * | 2.33 x |
Net Debt 2024 * | 196M | Net cash position 2025 * | 49.54M | EV / Sales 2025 * | 1.8 x |
P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
16
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.74% |
Latest transcript on Pacira BioSciences, Inc.
1 day | +0.62% | ||
1 week | +5.25% | ||
Current month | +1.53% | ||
1 month | +16.21% | ||
3 months | +4.60% | ||
6 months | +7.34% | ||
Current year | -8.73% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Charles Reinhart
DFI | Director of Finance/CFO | 63 | 11-10-31 |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 25 M€ | -4.18% | - | |
0.18% | 43 M€ | +2.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 30.8 | +0.90% | 65 481 |
24-06-04 | 30.52 | -1.20% | 880,566 |
24-06-03 | 30.89 | +1.85% | 652,731 |
24-05-31 | 30.33 | -0.43% | 717,143 |
24-05-30 | 30.46 | +4.10% | 606,715 |
Delayed Quote Nasdaq, June 05, 2024 at 11:28 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.73% | 1.42B | |
+42.51% | 750B | |
+34.11% | 606B | |
-6.25% | 356B | |
+18.79% | 326B | |
+6.32% | 286B | |
+18.49% | 246B | |
-3.31% | 213B | |
+11.30% | 213B | |
+2.14% | 167B |
- Stock Market
- Equities
- PCRX Stock